-
Cypralis to present pre-clinical data on novel cyclophilin D inhibitor CC-1233 for acute pancreatitis at the American Pancreatic Association meeting
Cambridge, UK, 9th November 2017 / Sciad Newswire / Cypralis, in collaboration with the University of Liverpool, will present in-vitro and in-vivo data obtained using novel cyclophilin inhibitor CC-1233 in models of acute pancreatitis at the American Pancreatic Association annual meeting in San Diego (Nov. 8-11th, 2017). CC-1233 is a potent inhibitor of cyclophilin D that maintains…
-
Professor Trevor Jones interviews industry leaders at Pharma Integrates 2017
London, UK, 26th October 2017 / Sciad Newswire / This year’s Pharma Integrates conference in London, 15th-16th November, will host industry leaders discussing some of the year’s hottest topics. Prof Trevor Jones, Board member & Chairman, eTherapeutics & Simbec Orion Research, will interview Dr. Ian Hudson, CEO of the MHRA, and Dr. Franz Humer, Director and former…
-
Life science innovators to share strategic insights at World HealthEx Forum 2017
London, UK, 23th October 2017 / Sciad Newswire / More than 150 C-level executives from leading life science companies will exchange experiences, learnings, and strategic insights with peers at Biotech and Money’s World HealthEx Forum on 13 November 2017. The event will host eight sub-sector forums where innovators across immuno-oncology, cell and gene therapy, digital health, medtech, neuroscience and the central…
-
BioMoti, Pharmidex and Queen Mary University of London secure £662,222 Biomedical Catalyst award
London, UK, 16th October 2017 / Sciad Newswire / BioMoti, Pharmidex and Queen Mary University of London (QMUL) have been awarded a grant of £662,222 by the UK’s innovation agency, Innovate UK. The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple…
-
Industry leaders to discuss the future of healthcare at World HealthEx Forum 2017
London, UK, 12th October 2017 / Sciad Newswire / Industry leaders will discuss the future of healthcare at Biotech and Money’s World HealthEx Forum on 13th November 2017. The inaugural event brings together board-level executives from across the life science sector who are involved in shaping the future of health. Sir Richard Sykes, Chairman of the NHS Trust, will present the…
-
World HealthEx Forum Keynote Speaker Update
The World HealthEx Forum – the ‘Davos’ of Life Sciences, will bring 250+ leading minds, KOLs and commercial leaders together under one roof for eight industry sub-sector leaders forums. The 13th November sees invite only, Chatham House Rule discussions and case studies from some of the world’s leading minds across pharma, biotech, government, payers and providers. The day will finish with a clear roadmap and…
-
Double Helix Technologies teams-up with Agilent Technologies to offer the SureVector Cloning System
Double Helix Technologies (Doulix) announced today a collaboration with Agilent Technologies Inc. (NYSE: A) to promote Agilent’s SureVector next-generation cloning kits through Doulix’s web platform. Through this partnership, synthetic biologists will be able to choose among SureVector’s standard DNA parts to design custom plasmids using Doulix’s web platform
-
Synpromics wins best emerging UK synthetic biotech company at OBN Awards
Edinburgh, UK, 6th October 2017 / Sciad Newswire / Synpromics is thrilled to announce they have been awarded Best Emerging UK Synthetic Biotech Company at the 9th Annual OBN Awards celebration last night. Synpromics was nominated on the strength of being the leader in gene control, improving human health by enabling safer, more effective cell and…
-
Edison issues free strategic overview on future of T-cell therapies for cancer
London, UK, 28th September 2017 / Sciad Newswire / The US approval of Novartis’s Kymriah for childhood leukaemia opens a dramatic new era of cancer therapy deploying powerful modified white cells (CAR-T cells) to selectively kill cancer cells. However, Kymriah and other expected first wave CD19-targeting CAR-T therapies only cover 1.4% of cancers in the US…
-
Medherant signs agreement with leading Japanese transdermal patch company for evaluation of its TEPI Patch® drug delivery system
Medherant, a leader in next-generation transdermal drug delivery, has signed an agreement with a Japanese transdermal patch company (“the company”), one of the world’s largest patch developers and manufacturers, to evaluate the potential of its TEPI Patch® technology to deliver a drug provided by the company.